Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.52 |
| ▸ | LIPG | Q9Y5X9 | 14/20 | 0.47 |
| ▸ | LPL | P06858 | 13/20 | 0.47 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31643226 | 1.00 | ROCK1 (0.52) | ROCK1LIPGLPLF11EGFR | |
| SCHEMBL28052007 | 0.88 | ROCK1 (0.50) | ROCK1LIPGLPLF11EGFR | |
| SCHEMBL15465471 | 0.87 | LIPG (0.47) | ROCK1LIPGLPLF11EGFR | |
| SCHEMBL18643675 | 0.85 | ROCK1 (0.56) | ROCK1LIPGLPLF11EGFR | |
| SCHEMBL22664432 | 0.84 | ROCK1 (0.50) | ROCK1LIPGLPLF11EGFR | |
| SCHEMBL3321140 | 0.84 | ROCK1 (0.55) | ROCK1LIPGLPLF11EGFR | |
| SCHEMBL17430653 | 0.84 | ROCK1 (0.52) | ROCK1LIPGLPLF11EGFR | |
| SCHEMBL793337 | 0.83 | LIPG (0.57) | ROCK1LIPGLPLF11EGFR | |
| SCHEMBL3233480 | 0.82 | LPL (0.44) | ROCK1LIPGLPLF11CA1 | |
| SCHEMBL20665867 | 0.81 | ROCK1 (0.50) | ROCK1LIPGLPLF11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037324-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| EP-3478672-B1 | BIARYLMETHYL HETEROCYCLES | UNIV MONTREAL (CA) | 2024-04-10 | — | — | EP | disclosed |
| CN-115960094-A | Preparation and application of aromatic ring substituted methylamine derivative | 上海璎黎药业有限公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | Université de Montréal (CA) | 2023-02-09 | — | — | US | disclosed |
| US-11407733-B2 | Biarylmethyl heterocycles | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-08-09 | — | — | US | disclosed |
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-08-02 | — | — | US | disclosed |
| CN-107660205-B | Heterocyclic compounds as LSD1 inhibitors | 因赛特公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | INCYTE CORPORATION | 2020-12-17 | — | — | US | disclosed |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-10-13 | — | — | US | disclosed |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-05-05 | — | — | US | disclosed |
| US-9012445-B2 | Substituted 4-(1H-pyrazol-4-yl)benzyl analogues as positive allosteric modulators of mAChR M1 receptors | VANDERBILT UNIVERSITY (US) | 2015-04-21 | — | — | US | disclosed |
| US-8962648-B2 | Tricyclic compounds and PBK inhibitors containing the same | ONCOTHERAPY SCIENCE, INC. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20140206676-A1 | SUBSTITUTED 4-(1H-PYRAZOL-4-YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206676-A1 | SUBSTITUTED 4-(1H-PYRAZOL-4-YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140206676-A1 | SUBSTITUTED 4-(1H-PYRAZOL-4-YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2014-07-24 | — | — | US | disclosed |
| WO-2013106795-A1 | SUBSTITUTED 4-(1H~PYRAZOL-4.YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013106795-A1 | SUBSTITUTED 4-(1H~PYRAZOL-4.YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS | VANDERBILT UNIVERSITY (US) | 2013-07-18 | — | — | WO | disclosed |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2013-07-11 | — | — | US | disclosed |
| EP-2552206-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | OncoTherapy Science, Inc. (JP) | 2013-02-06 | — | — | EP | disclosed |
| WO-2011123419-A1 | TRYCYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | ONCOTHERAPY SCIENCE, INC. (JP) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11401272-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | ROCK1 1257/4885LIPG 1842/4885LPL 3226/4885 |
| US-20200392143-A1 | HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, DOT1L | ROCK1 1257/4885LIPG 1842/4885LPL 3226/4885 |
| US-20140206676-A1 | SUBSTITUTED 4-(1H-PYRAZOL-4-YL)BENZYL ANALOGUES AS POSITIVE ALLOSTERIC MODULATORS OF MACHR M1 RECEPTORS | CHRM1, CHRM4, CHRM5 | ROCK1 662/4885LIPG 4617/4885LPL 3555/4885 |
| US-11407733-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | ROCK1 1523/4885LIPG 2418/4885LPL 3432/4885 |
| US-20130178459-A1 | TRICYCLIC COMPOUNDS AND PBK INHIBITORS CONTAINING THE SAME | PBDC1, SBK1, PLK2 | ROCK1 3525/4885LIPG 3497/4885LPL 4071/4885 |
| US-12037324-B2 | Biarylmethyl heterocycles | ARRB1, ADRB2, ADRB1 | ROCK1 1523/4885LIPG 2418/4885LPL 3432/4885 |
| US-10800779-B2 | Heterocyclic compounds as LSD1 inhibitors | KDM1B, KDM1A, DOT1L | ROCK1 1257/4885LIPG 1842/4885LPL 3226/4885 |
| US-10640503-B2 | Imidazopyridines and imidazopyrazines as LSD1 inhibitors | KDM5A, KDM1A, KDM1B | ROCK1 832/4885LIPG 4054/4885LPL 4359/4885 |
| US-20230045357-A1 | BIARYLMETHYL HETEROCYCLES | ARRB1, ADRB2, ADRB1 | ROCK1 1523/4885LIPG 2418/4885LPL 3432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.